{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Prototype data Precessing with Spacy"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "1. Import model\r\n",
    "2. Import database\r\n",
    "3. iterate through database and label the data\r\n",
    "4. Create DF with labeled data as features\r\n",
    "5. Export DF as 'results.csv'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\r\n",
    "import pandas as pd \r\n",
    "import numpy as np "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading the Model\r\n",
    "\r\n",
    "nlp = spacy.load(\"../training/test_model\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading the input_data\r\n",
    "\r\n",
    "data = pd.read_csv(\"input_data_filtered.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "data[\"PrimaryOutcomeMeasure\"] = data[\"PrimaryOutcomeMeasure\"].astype(str)\r\n",
    "data[\"PrimaryTimeFrame\"] = data[\"PrimaryTimeFrame\"].astype(str)\r\n",
    "data[\"SecondaryOutcomeMeasure\"] = data[\"SecondaryOutcomeMeasure\"].astype(str)\r\n",
    "data[\"SecondaryTimeFrame\"] = data[\"SecondaryTimeFrame\"].astype(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_result_df = pd.DataFrame(columns=[\"NCTId\", \"Condition\", 'Change', \"Reference\", \"Variable\",\"Timepoint\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>NCTId</th>\n      <th>Condition</th>\n      <th>Change</th>\n      <th>Reference</th>\n      <th>Variable</th>\n      <th>Timepoint</th>\n    </tr>\n  </thead>\n  <tbody>\n  </tbody>\n</table>\n</div>",
      "text/plain": "Empty DataFrame\nColumns: [NCTId, Condition, Change, Reference, Variable, Timepoint]\nIndex: []"
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_result_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children'], 'Reference': [], 'Variable': ['Documented Risk Factors'], 'Timepoint': []}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children'], 'Reference': ['Validation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm'], 'Timepoint': []}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics'], 'Change': ['Number of Children', 'outcome'], 'Reference': ['Validation', 'comparison'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)'], 'Timepoint': []}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants'], 'Reference': ['Validation', 'comparison'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)'], 'Timepoint': []}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers'], 'Timepoint': []}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie'], 'Timepoint': []}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model ['], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\"], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743', 'NCT01472185'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24', 'Change', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)', 'HbA1c', 'Fasting Serum Glucose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21', 'Week 24', 'Week 24|Percentage', 'Week 24|Change From', '2-hour Postprandial', 'Week 24|Change From', '2-hour Postprandial', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743', 'NCT01472185', 'NCT01494987'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24', 'Change', 'Change', 'Change', 'Change', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)', 'HbA1c', 'Fasting Serum Glucose', 'HbA1c', 'Fasting Serum Glucose'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21', 'Week 24', 'Week 24|Percentage', 'Week 24|Change From', '2-hour Postprandial', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', 'Week 24', '2-hour Postprandial', 'Week 24|Change From', 'Week 24|Change From', '2-hour Postprandial', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743', 'NCT01472185', 'NCT01494987', 'NCT02343471'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Healthy|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24', 'Change', 'Change', 'Change', 'Change', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)', 'HbA1c', 'Fasting Serum Glucose', 'HbA1c', 'Fasting Serum Glucose', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).', 'Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon-like peptide 1', 'Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min).'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21', 'Week 24', 'Week 24|Percentage', 'Week 24|Change From', '2-hour Postprandial', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', 'Week 24', '2-hour Postprandial', 'Week 24|Change From', 'Week 24|Change From', '2-hour Postprandial', 'Week 24']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743', 'NCT01472185', 'NCT01494987', 'NCT02343471', 'NCT01755468'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Healthy|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24', 'Change', 'Change', 'Change', 'Change', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)', 'HbA1c', 'Fasting Serum Glucose', 'HbA1c', 'Fasting Serum Glucose', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).', 'Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon-like peptide 1', 'Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min).', 'Secretion-Sensitivity Index-2 (ISSI-2).'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21', 'Week 24', 'Week 24|Percentage', 'Week 24|Change From', '2-hour Postprandial', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', 'Week 24', '2-hour Postprandial', 'Week 24|Change From', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', '2 years', '2-years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743', 'NCT01472185', 'NCT01494987', 'NCT02343471', 'NCT01755468', 'NCT04363710'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Healthy|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus in Obese'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24', 'Change', 'Change', 'Change', 'Change', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'liter', 'BMI'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)', 'HbA1c', 'Fasting Serum Glucose', 'HbA1c', 'Fasting Serum Glucose', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).', 'Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon-like peptide 1', 'Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min).', 'Secretion-Sensitivity Index-2 (ISSI-2).', 'HbA1c', 'percentage|Fasting Blood Glucose', 'Fasting Insulin Level'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21', 'Week 24', 'Week 24|Percentage', 'Week 24|Change From', '2-hour Postprandial', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', 'Week 24', '2-hour Postprandial', 'Week 24|Change From', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', '2 years', '2-years']}\n",
      "Series([], Name: NCTId, dtype: object)\n",
      "{'NCTId': ['NCT01814787', 'NCT01346033', 'NCT04765631', 'NCT03979768', 'NCT02286128', 'NCT03362762', 'NCT01920256', 'NCT03840850', 'NCT00392678', 'NCT03159221', 'NCT00485758', 'NCT03044860', 'NCT02355145', 'NCT01257087', 'NCT03130894', 'NCT02440555', 'NCT02327429', 'NCT03259321', 'NCT04016584', 'NCT00810823', 'NCT01601574', 'NCT03243136', 'NCT01021865', 'NCT01055652', 'NCT02290860', 'NCT04005261', 'NCT00612794', 'NCT01727349', 'NCT00239187', 'NCT01073020', 'NCT01249677', 'NCT01085292', 'NCT01182935', 'NCT02205996', 'NCT00240253', 'NCT00982371', 'NCT04031417', 'NCT01284465', 'NCT02226822', 'NCT01869608', 'NCT01184768', 'NCT04501991', 'NCT01010035', 'NCT01387984', 'NCT01237301', 'NCT04403841', 'NCT01088711', 'NCT03214380', 'NCT02322762', 'NCT00888836', 'NCT03447275', 'NCT00451620', 'NCT01845064', 'NCT02104804', 'NCT00787670', 'NCT01933256', 'NCT03406910', 'NCT01649466', 'NCT03464812', 'NCT02501876', 'NCT03341117', 'NCT04214600', 'NCT02860611', 'NCT01037647', 'NCT00103935', 'NCT00525330', 'NCT01977560', 'NCT01278823', 'NCT01580475', 'NCT00108004', 'NCT02222350', 'NCT02528695', 'NCT00922649', 'NCT03324776', 'NCT04163757', 'NCT00971659', 'NCT01607294', 'NCT00299871', 'NCT00303394', 'NCT00631774', 'NCT04072523', 'NCT02065544', 'NCT00837408', 'NCT03909269', 'NCT00477581', 'NCT00799643', 'NCT01640873', 'NCT01732705', 'NCT01159249', 'NCT00106808', 'NCT04176276', 'NCT01663220', 'NCT03902288', 'NCT03538743', 'NCT01472185', 'NCT01494987', 'NCT02343471', 'NCT01755468', 'NCT04363710', 'NCT00562029'], 'Condition': ['Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetics', 'Type2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes.|Correlation', 'type 2 diabetes', 'Type 2 Diabetes Treated With Insulin', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Childhood Obesity', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes|Percentage', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', '6%', 'Type 2 Diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|To', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 diabetes', 'Type2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Overweight|Obesity', 'Type2 Diabetes', 'Type 2 diabetes', 'Coronary Artery Disease|Diabetes Mellitus Type 2', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes.|To', 'type 2 diabetes', 'Diabetes, Gestational', 'Type 2 Diabetes Treated With Insulin', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus|Obesity', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type II diabetes', 'type II diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Metabolic Control', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes (T2D)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency', 'Type 2 Diabetes', 'type 2 diabetes', 'Diabetes Type 2', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Obesity|Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes|Heart Diseases', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type2 Diabetes', 'Alzheimer´s Disease|Diabetes Mellitus Type 2', 'type 2', 'Diabetes Mellitus, Type 2|Antioxidant Enzyme System', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes|Depression', 'Type 1 Diabetes|Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Obesity|Type 2 Diabetes', 'type 2 DM', 'type 2 dm', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes Mellitus Type 2', 'Type 2 Diabetes', 'Type2 Diabetes', 'Type 2 Diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Hyperlipidemia|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes|assess', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes|Obesity', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetes|Hypertension', 'Type 2 Diabetes', 'Diabetic Nephropathy Type 2|Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Kidney Disease|Type2 Diabetes', 'Type 2 Diabetes', 'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Healthy|Type 2 Diabetes', 'type 2 diabetes', 'type 2 diabetes', 'Type 2 Diabetes', 'Type 2 Diabetes Mellitus in Obese', 'Type 2 Diabetes Mellitus', 'Type 2 Diabetes'], 'Change': ['Number of Children', 'outcome', 'Number of Participants', 'number of participants', 'Characteristic', 'Change', 'Change', 'complications|Change', 'Binary outcome', 'Change', 'Change in HbA1c|Change', 'Tolerability|Change in Insulin', 'Change in Body', 'Change', 'Cholesterol', 'Change', 'Change', 'Change', 'Number of years', 'HbA1c of', 'Percentage', 'Change in Energy', 'Change in Hemoglobin', 'Circumference|Change', 'Cholesterol|Change', 'Change in HbA1c', 'Secondary Endpoints|Secondary Endpoints|Secondary', 'HbA1c', 'Measure', 'Control, as', 'Improvements', 'Number of subjects', '2000', 'Calcium, vitamin', 'Classes of diabetic', 'Number of subjects', 'Number of subjects', 'Change in Hemoglobin', 'Number of Participants', 'AE)|Number of Participants', 'Change', 'Secondary endpoints', 'Change in HbA1c', 'Change in Postprandial', 'Change', 'Analysis of Change', '24)|Analysis of Change', 'Modification', 'Modification', 'Change of Glycated', 'Change of Depression', '27).|Change', '27)|Change', '27)|Change', 'Control', 'Changes', 'change', 'change', 'level|change', 'level|change', 'level|change', 'Assessment of', 'Change in HbA1c', 'Change', 'Secretagogue, Metformin', 'Number of Participants', 'Geometric Mean Plasma', 'Concentrations', 'Change in HBA1c', 'Change', 'Number of Participants', 'TEAEs)|Number of Participants', 'Abnormality|Number of Participants', 'AUC24', 'Change', 'Change', 'Change', 'Change', 'Change', 'Change'], 'Reference': ['Validation', 'comparison', 'Correlation', 'Correlation', 'patients', 'relation', 'baseline', 'baseline', 'baseline', 'baseline', 'baseline', 'investigators', 'Recall', 'Baseline', 'Baseline', 'Trends', 'Baseline', 'intestinal', 'patients', 'complications|Percentage', 'Percentage', 'Reduction', 'cost', 'remission', 'C', 'relation', 'serum', 'safety', 'baseline', 'changes', 'baseline', 'line', 'profile', 'removal', 'patients', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'mellitus', 'urine', 'urine', 'urine', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'baseline', 'baseline', 'baseline', 'profile', 'safety', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'setting', 'patients', 'patients', 'baseline', 'safety', 'profile', 'baseline', 'baseline', 'baseline', 'Fructosamine', 'safety', 'based', 'Correlation', 'Baseline', 'Baseline', 'Compared', 'Baseline', 'Reduction', 'Reduction', 'Baseline', 'AEs', 'baseline', 'baseline', 'baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'Baseline', 'liter', 'BMI', 'Resolution'], 'Variable': ['Documented Risk Factors', 'SCOUT DS algorithm', 'total volumetric bone mineral density (vBMD)', 'risk test only (RTO)- group', 'HbA1c-measurement (HbA1c-group)', 'NF-кB dependent-proinflammation markers', 'osteoblast-specific gene expression in the MSC', 'NF-кB dependent-proinflammation markers', 'NF-кB dependent-proinflammation markers', 'insulin', 'rate of HbAC', 'plan of insulinothérapie', 'A1C (glycated hemoglobin)', 'lipids', 'blood pressure', 'Quality of life', 'insulin satisfaction', 'intervention', 'personalised risk information|Intentions to make', 'lifestyle changes|Change', 'self-management behaviour', 'HbA1c', 'Fasting Glucose', 'Insulin', 'C-peptide, Homeostasis Model [', 'C-peptide, Homeostasis Model [', 'status)', 'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight', 'status)|Food intake|Family communication', 'Self-esteem|Teen Quality of Life', 'Baseline (Bl) in', 'Baseline (Bl)', 'Density Lipoprotein Cholesterol in', 'Baseline (Bl)', 'patients with', 'used classes of drugs|Number of years', 'Fasting Blood Glucose', 'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events', 'screening accessibility to population from the priority health area', 'numbers of patients screened by self-administered questionnaire', 'Food Record)|Change in Carbohydrate Intake (3-day', 'Food Record)|Change in', 'Protein Intake (3-day', 'Food Record)|Change in Total Fat Intake (3-day', 'Food Record)|Change in Saturated Fat Intake (3-day', 'Food Record)|Change in Dietary Fibre Intake (3-day', 'Food Record)|Change in', 'Added Sucrose Intake (3-day', 'Food Record)|Change in Sodium Intake (3-day', 'Food Record)|Change in Calcium Intake (3-day', 'Food Record)|Change in', 'A1c)|Change', 'BMI)|Change', 'Fasting Triglyceride|Change', 'Fasting Total', 'Fasting Low-density Lipoprotein Cholesterol|Change', 'Fasting High-density Lipoprotein Cholesterol', 'polyunsaturated fatty acids intake', 'Success (evaluated by a', 'Yes/No format)', 'insulin education program, Diabetes', 'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'voglibose', 'Japanese patients with', 'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with', 'AUC0-t, tmax,', 'fasting C-peptide concentrations|Correlations of fasting', 'patients characteristics', 'pharmacokinetics of exenatide administered once weekly by SC injection', 'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with', 'postprandial glucose concentrations', 'G1', 'pharmacokinetics (PK)', 'G1', 'Fasting Plasma Glucose', 'HbA1c', 'patients with', 'pharmacodynamics of NOX-E36 in healthy subjects', 'patients with', 'blood glucose levels', 'C-reactive protein)', 'regimen of insulin glargine in subjects with', 'regimen of insulin glargine in subjects with', 'lipids', 'patient-reported outcomes.', 'vitamin K dietary intakes; TUG (sec); grip', 'total body; physical activity', 'patients with', 'rank test', 'self-management behaviors', 'blood glucose target goals|Blood glucose level change from', 'baseline|Blood pressure change', 'profile changes', 'Quality of Life', 'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications', 'Diagnosis of abnormal glucose tolerance', 'D status on glucose tolerance', 'Diurnal Median Curve)|Percent of Time', 'CGM Glucose', 'After Day', 'Inhibition of DPP-4', 'After Day 22|WAA', 'Concentration|Plasma Glucose', 'During Mixed-Meal Tolerance Test (MMTT)', 'Documented Symptomatic Hypoglycemia|Change', 'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at', 'Lifestyle Flexibility Domain Score at', 'real-world setting.', 'reducing body weight', 'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular', 'total remission of type', 'blood pressure, cholesterol', 'quality of life', 'serum vitamin B12 levels between cases', 'serum vitamin', 'serum vitamin B6 concentrations', 'serum vitamin B12 between patients with', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vitamin B6 vitamers between', 'patients with', 'vascular risk', 'postprandial glucose levels in elderly people with', 'pharmacokinetic of DM199 after single', 'Therapeutic Glycaemic Response of HbA1c', 'Fasting Plasma Glucose', 'Average of Weeks 20', 'Total Daily Dose of Insulin From Baseline', 'loss decreases the risk of CVD', 'loss reduces over time', 'risk of CVD in morbidly obese subjects with T2DM.', 'Percentage', 'patients reaching HbA1c below 7.0% without confirmed hypoglycemia', 'gain|Rate of confirmed hypoglycemic events', 'reach their blood glucose target (HbA1c below 7.0%)', 'Medication (TSQM-9)', 'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction', \"Alzheimer's disease (AD)\", \"Alzheimer's disease (AD)\", 'administration of Acetylsalicylic Acid|Hepatic safety after the', 'administration of Acetylsalicylic Acid|Modification in fasting glucose', 'administration of Acetylsalicylic acid', 'Cognitive Behavioral Therapy Sessions', 'Depression Index', 'VLDL-TG production', 'VLDL-TG oxidation|VLDL-TG subcutaneous adipose', 'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)', 'parameters of exenatide LAR administered weekly', 'Mellitus|Change', 'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with', 'post-prandial glucose dynamics', 'insulin sensitivity (homeostasis model index', 'pancreatic beta cell', 'retraining (9 months)', 'blood glucose', 'blood glucose|change', 'blood fasting plasma glucose', 'blood plasma glucose level|change', 'blood insulin', 'blood C-peptide level|change in blood active', 'blood PYY', 'level|change', 'blood HbA1c level|change', 'blood glycoalbumin', 'Insulin', 'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body', '16', 'Percentage', 'patients having HbA1c under 7%|Percent of time', 'Blood glucose (BG)', 'blood glucose excursion (AUCBG0-6h)', 'blood glucose (BG)', 'profiles, fasting', 'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid', 'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with', 'postprandial glucose', 'HbA1c', 'C-peptide, glucagon.', 'Insulin', 'C peptide', 'insulin|Fasting plasma glucose (FPG)|Serum cytokine', 'Insulin-sensitivity index derived from', 'insulin', 'subgroup of patients, insulin-sensitivity assessed by clamp', 'profiles derived from muscle', 'quality of life', 'profile|HS-C Reactive Protein|Aerobic Fitness', 'HbA1c', 'total mean glucose from continuous glucose monitoring', 'variation|Low Blood Glucose', 'Blood Glucose', 'range below 3.0 mmol/l|Time', 'range below 3.9 mmol/l', 'Fasting Glucose', 'Fasting Glucose', 'Reduction in HbA1c of ≥0.5%,', 'HbA1c', 'C], TC/HDL-C Ratio,', 'LDL-C/HDL-C Ratio)|Changes in WBC', 'Differential, High-sensitivity C Reactive Protein (hsCRP)', 'Rescue Therapy;', 'Discontinuation of Study Medication|Response Rates in', 'Lifestyle Modification,', 'Combination Therapy', 'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)', 'After Single and Multiple Drug Doses', 'Weighted Mean Glucose (WMG)|Change From', 'HBA1c|Fasting Plasma Glucose|Fasting', 'Insulin|Fasting C', 'HDL-C', 'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25', 'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement', 'total antioxidant activity measurement', 'All-causality', 'Laboratory Abnormalities Without Regard to Baseline', 'Abnormal Vital Signs|Number of Participants With', 'Abnormal Electrocardiogram (ECG) Interval', 'AUCtau of PF-06882961 on Day 1', 'Day 28|Maximum Plasma Concentration (Cmax)', 'Day 28|Terminal Half-life (t½)', 'Recovered in Urine', 'Hours (Ae24)', 'Clearance (CLr)', 'HbA1c', 'Fasting Serum Glucose', 'HbA1c', 'Fasting Serum Glucose', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey', 'protein as pre-meal after a high-fat meal in healthy subjects', 'Curve (iAUC -15 - 360 min).', 'Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min)|Glucagon-like peptide 1', 'Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the', 'Curve (AUC -15 - 360 min).', 'Secretion-Sensitivity Index-2 (ISSI-2).', 'HbA1c', 'percentage|Fasting Blood Glucose', 'Fasting Insulin Level'], 'Timepoint': ['12 months', '12 months|Change', '12 months|All', '12 months|Change', '12 months', '14-week', '6 months', '12 months', 'Week (', '12 Compared', 'Week (', '12 Compared', 'Week (', '12 Compared', '2 time', '3-day', '3-day Food Record)', '3 years', 'Week 26', '1,5-Anhydroglucitol (1,5-AG)', 'Week 26|Change From', '10-Point Self-Monitoring Blood Glucose (SMBG)', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Change From', 'Week 26|Number', '<7%', '2 diabetes', 'Week 24', 'Week 24', '120-minute', 'Week 24', 'Week 24', 'Week 24', '24 week', '14 and Week 15', '21 months', '3 months', 'Week 16|Ratio', 'Week 16|Number of daily', 'Week 16', '13 weeks', '6-point self-monitored blood glucose (SMBG)', '2 Hours Oral Glucose Tolerance Test', 'Week 24', 'Week 24|Change from', '14 or 21', '14 or 21', '14 or 21', 'Week 24', 'Week 24|Percentage', 'Week 24|Change From', '2-hour Postprandial', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', 'Week 24', '2-hour Postprandial', 'Week 24|Change From', 'Week 24|Change From', '2-hour Postprandial', 'Week 24', '2 years', '2-years']}\n"
     ]
    }
   ],
   "source": [
    "# Iteration through data \r\n",
    "# TODO: Remove Measurment-Title ???\r\n",
    "# TODO: Process for multi-row data\r\n",
    "\r\n",
    "\r\n",
    "dictTest = {\"NCTId\":[],\"Condition\":[],\"Change\":[],\"Reference\":[], \"Variable\" :[], \"Timepoint\":[]}\r\n",
    "for index, row in data.iterrows():\r\n",
    "\r\n",
    "    trial_id = row[1]\r\n",
    "    dictTest[\"NCTId\"].append(trial_id)\r\n",
    "    print(data_result_df[\"NCTId\"])\r\n",
    "\r\n",
    "    condition = row[2]\r\n",
    "    dictTest[\"Condition\"].append(condition)\r\n",
    "\r\n",
    "    primary_endpoint = row[3]\r\n",
    "    primary_endpoints = []\r\n",
    "\r\n",
    "    primary_endpoint_timepoint = row[4]\r\n",
    "    primary_endpoint_timepoints = []\r\n",
    "\r\n",
    "    secondary_endpoint = row[5]\r\n",
    "    secondary_endpoints = []\r\n",
    "\r\n",
    "    secondary_endpoint_timepoint = row[6]\r\n",
    "    secondary_endpoint_timepoints = []\r\n",
    "\r\n",
    "    if  primary_endpoint.find(\"|\") == 1:\r\n",
    "        primary_endpoints = primary_endpoint.split(\"|\")\r\n",
    "        print(primary_endpoints)\r\n",
    "\r\n",
    "    if  primary_endpoint_timepoint.find(\"|\") == 1:\r\n",
    "        primary_endpoint_timepoints = primary_endpoint_timepoint.split(\"|\")\r\n",
    "        print(primary_endpoint_timepoint)\r\n",
    "\r\n",
    "\r\n",
    "    if  secondary_endpoint.find(\"|\") == 1:\r\n",
    "        secondary_endpoints = secondary_endpoint.split('|')\r\n",
    "        print(secondary_endpoint)\r\n",
    "\r\n",
    "    if  secondary_endpoint_timepoint.find(\"|\") == 1:\r\n",
    "        secondary_endpoint_timepoints = secondary_endpoint_timepoint.split('|')\r\n",
    "        print(secondary_endpoint_timepoint)\r\n",
    "\r\n",
    "\r\n",
    "    target = nlp(primary_endpoint)\r\n",
    "    for entity in target.ents:\r\n",
    "        dictTest[entity.label_].append(entity.text)\r\n",
    "\r\n",
    "\r\n",
    "    target = nlp(secondary_endpoint)\r\n",
    "\r\n",
    "    for entity in target.ents:\r\n",
    "        dictTest[entity.label_].append(entity.text)\r\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": "{'NCTId': ['NCT01814787',\n  'NCT01346033',\n  'NCT04765631',\n  'NCT03979768',\n  'NCT02286128',\n  'NCT03362762',\n  'NCT01920256',\n  'NCT03840850',\n  'NCT00392678',\n  'NCT03159221',\n  'NCT00485758',\n  'NCT03044860',\n  'NCT02355145',\n  'NCT01257087',\n  'NCT03130894',\n  'NCT02440555',\n  'NCT02327429',\n  'NCT03259321',\n  'NCT04016584',\n  'NCT00810823',\n  'NCT01601574',\n  'NCT03243136',\n  'NCT01021865',\n  'NCT01055652',\n  'NCT02290860',\n  'NCT04005261',\n  'NCT00612794',\n  'NCT01727349',\n  'NCT00239187',\n  'NCT01073020',\n  'NCT01249677',\n  'NCT01085292',\n  'NCT01182935',\n  'NCT02205996',\n  'NCT00240253',\n  'NCT00982371',\n  'NCT04031417',\n  'NCT01284465',\n  'NCT02226822',\n  'NCT01869608',\n  'NCT01184768',\n  'NCT04501991',\n  'NCT01010035',\n  'NCT01387984',\n  'NCT01237301',\n  'NCT04403841',\n  'NCT01088711',\n  'NCT03214380',\n  'NCT02322762',\n  'NCT00888836',\n  'NCT03447275',\n  'NCT00451620',\n  'NCT01845064',\n  'NCT02104804',\n  'NCT00787670',\n  'NCT01933256',\n  'NCT03406910',\n  'NCT01649466',\n  'NCT03464812',\n  'NCT02501876',\n  'NCT03341117',\n  'NCT04214600',\n  'NCT02860611',\n  'NCT01037647',\n  'NCT00103935',\n  'NCT00525330',\n  'NCT01977560',\n  'NCT01278823',\n  'NCT01580475',\n  'NCT00108004',\n  'NCT02222350',\n  'NCT02528695',\n  'NCT00922649',\n  'NCT03324776',\n  'NCT04163757',\n  'NCT00971659',\n  'NCT01607294',\n  'NCT00299871',\n  'NCT00303394',\n  'NCT00631774',\n  'NCT04072523',\n  'NCT02065544',\n  'NCT00837408',\n  'NCT03909269',\n  'NCT00477581',\n  'NCT00799643',\n  'NCT01640873',\n  'NCT01732705',\n  'NCT01159249',\n  'NCT00106808',\n  'NCT04176276',\n  'NCT01663220',\n  'NCT03902288',\n  'NCT03538743',\n  'NCT01472185',\n  'NCT01494987',\n  'NCT02343471',\n  'NCT01755468',\n  'NCT04363710',\n  'NCT00562029'],\n 'Condition': ['Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetics',\n  'Type2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes.|Correlation',\n  'type 2 diabetes',\n  'Type 2 Diabetes Treated With Insulin',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'Diabetes Mellitus, Type 2|Childhood Obesity',\n  'Diabetes Mellitus Type 2',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'type 2 diabetes|Percentage',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus|Obesity',\n  'Type 2 Diabetes',\n  '6%',\n  'Type 2 Diabetes',\n  'Type2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes|To',\n  'Type 2 Diabetes',\n  'Type2 Diabetes',\n  'Type 2 diabetes',\n  'Type2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes|Overweight|Obesity',\n  'Type2 Diabetes',\n  'Type 2 diabetes',\n  'Coronary Artery Disease|Diabetes Mellitus Type 2',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'type 2 diabetes.|To',\n  'type 2 diabetes',\n  'Diabetes, Gestational',\n  'Type 2 Diabetes Treated With Insulin',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus|Obesity',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'type II diabetes',\n  'type II diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes|Metabolic Control',\n  'Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes (T2D)',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Diabetes Type 2',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Obesity|Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'Type 2 Diabetes|Heart Diseases',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type2 Diabetes',\n  'Alzheimer´s Disease|Diabetes Mellitus Type 2',\n  'type 2',\n  'Diabetes Mellitus, Type 2|Antioxidant Enzyme System',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes|Depression',\n  'Type 1 Diabetes|Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Obesity|Type 2 Diabetes',\n  'type 2 DM',\n  'type 2 dm',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Diabetes Mellitus Type 2',\n  'Type 2 Diabetes',\n  'Type2 Diabetes',\n  'Type 2 Diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Hyperlipidemia|Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes|assess',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes|Obesity',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Diabetes|Hypertension',\n  'Type 2 Diabetes',\n  'Diabetic Nephropathy Type 2|Type2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus',\n  'Diabetic Kidney Disease|Type2 Diabetes',\n  'Type 2 Diabetes',\n  'Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes Mellitus',\n  'Healthy|Type 2 Diabetes',\n  'type 2 diabetes',\n  'type 2 diabetes',\n  'Type 2 Diabetes',\n  'Type 2 Diabetes Mellitus in Obese',\n  'Type 2 Diabetes Mellitus',\n  'Type 2 Diabetes'],\n 'Change': ['Number of Children',\n  'outcome',\n  'Number of Participants',\n  'number of participants',\n  'Characteristic',\n  'Change',\n  'Change',\n  'complications|Change',\n  'Binary outcome',\n  'Change',\n  'Change in HbA1c|Change',\n  'Tolerability|Change in Insulin',\n  'Change in Body',\n  'Change',\n  'Cholesterol',\n  'Change',\n  'Change',\n  'Change',\n  'Number of years',\n  'HbA1c of',\n  'Percentage',\n  'Change in Energy',\n  'Change in Hemoglobin',\n  'Circumference|Change',\n  'Cholesterol|Change',\n  'Change in HbA1c',\n  'Secondary Endpoints|Secondary Endpoints|Secondary',\n  'HbA1c',\n  'Measure',\n  'Control, as',\n  'Improvements',\n  'Number of subjects',\n  '2000',\n  'Calcium, vitamin',\n  'Classes of diabetic',\n  'Number of subjects',\n  'Number of subjects',\n  'Change in Hemoglobin',\n  'Number of Participants',\n  'AE)|Number of Participants',\n  'Change',\n  'Secondary endpoints',\n  'Change in HbA1c',\n  'Change in Postprandial',\n  'Change',\n  'Analysis of Change',\n  '24)|Analysis of Change',\n  'Modification',\n  'Modification',\n  'Change of Glycated',\n  'Change of Depression',\n  '27).|Change',\n  '27)|Change',\n  '27)|Change',\n  'Control',\n  'Changes',\n  'change',\n  'change',\n  'level|change',\n  'level|change',\n  'level|change',\n  'Assessment of',\n  'Change in HbA1c',\n  'Change',\n  'Secretagogue, Metformin',\n  'Number of Participants',\n  'Geometric Mean Plasma',\n  'Concentrations',\n  'Change in HBA1c',\n  'Change',\n  'Number of Participants',\n  'TEAEs)|Number of Participants',\n  'Abnormality|Number of Participants',\n  'AUC24',\n  'Change',\n  'Change',\n  'Change',\n  'Change',\n  'Change',\n  'Change'],\n 'Reference': ['Validation',\n  'comparison',\n  'Correlation',\n  'Correlation',\n  'patients',\n  'relation',\n  'baseline',\n  'baseline',\n  'baseline',\n  'baseline',\n  'baseline',\n  'investigators',\n  'Recall',\n  'Baseline',\n  'Baseline',\n  'Trends',\n  'Baseline',\n  'intestinal',\n  'patients',\n  'complications|Percentage',\n  'Percentage',\n  'Reduction',\n  'cost',\n  'remission',\n  'C',\n  'relation',\n  'serum',\n  'safety',\n  'baseline',\n  'changes',\n  'baseline',\n  'line',\n  'profile',\n  'removal',\n  'patients',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'mellitus',\n  'urine',\n  'urine',\n  'urine',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'baseline',\n  'baseline',\n  'baseline',\n  'profile',\n  'safety',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'setting',\n  'patients',\n  'patients',\n  'baseline',\n  'safety',\n  'profile',\n  'baseline',\n  'baseline',\n  'baseline',\n  'Fructosamine',\n  'safety',\n  'based',\n  'Correlation',\n  'Baseline',\n  'Baseline',\n  'Compared',\n  'Baseline',\n  'Reduction',\n  'Reduction',\n  'Baseline',\n  'AEs',\n  'baseline',\n  'baseline',\n  'baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'Baseline',\n  'liter',\n  'BMI',\n  'Resolution'],\n 'Variable': ['Documented Risk Factors',\n  'SCOUT DS algorithm',\n  'total volumetric bone mineral density (vBMD)',\n  'risk test only (RTO)- group',\n  'HbA1c-measurement (HbA1c-group)',\n  'NF-кB dependent-proinflammation markers',\n  'osteoblast-specific gene expression in the MSC',\n  'NF-кB dependent-proinflammation markers',\n  'NF-кB dependent-proinflammation markers',\n  'insulin',\n  'rate of HbAC',\n  'plan of insulinothérapie',\n  'A1C (glycated hemoglobin)',\n  'lipids',\n  'blood pressure',\n  'Quality of life',\n  'insulin satisfaction',\n  'intervention',\n  'personalised risk information|Intentions to make',\n  'lifestyle changes|Change',\n  'self-management behaviour',\n  'HbA1c',\n  'Fasting Glucose',\n  'Insulin',\n  'C-peptide, Homeostasis Model [',\n  'C-peptide, Homeostasis Model [',\n  'status)',\n  'Adherence|Family Problem-solving|Physical activity|Body Fat (weight status)|Waist Circumference (weight',\n  'status)|Food intake|Family communication',\n  'Self-esteem|Teen Quality of Life',\n  'Baseline (Bl) in',\n  'Baseline (Bl)',\n  'Density Lipoprotein Cholesterol in',\n  'Baseline (Bl)',\n  'patients with',\n  'used classes of drugs|Number of years',\n  'Fasting Blood Glucose',\n  'Doses/Number of Diabetes Medications Used Preoperatively|Number of Participants With Microvascular Events',\n  'screening accessibility to population from the priority health area',\n  'numbers of patients screened by self-administered questionnaire',\n  'Food Record)|Change in Carbohydrate Intake (3-day',\n  'Food Record)|Change in',\n  'Protein Intake (3-day',\n  'Food Record)|Change in Total Fat Intake (3-day',\n  'Food Record)|Change in Saturated Fat Intake (3-day',\n  'Food Record)|Change in Dietary Fibre Intake (3-day',\n  'Food Record)|Change in',\n  'Added Sucrose Intake (3-day',\n  'Food Record)|Change in Sodium Intake (3-day',\n  'Food Record)|Change in Calcium Intake (3-day',\n  'Food Record)|Change in',\n  'A1c)|Change',\n  'BMI)|Change',\n  'Fasting Triglyceride|Change',\n  'Fasting Total',\n  'Fasting Low-density Lipoprotein Cholesterol|Change',\n  'Fasting High-density Lipoprotein Cholesterol',\n  'polyunsaturated fatty acids intake',\n  'Success (evaluated by a',\n  'Yes/No format)',\n  'insulin education program, Diabetes',\n  'self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes',\n  'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with',\n  'voglibose',\n  'Japanese patients with',\n  'pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with',\n  'AUC0-t, tmax,',\n  'fasting C-peptide concentrations|Correlations of fasting',\n  'patients characteristics',\n  'pharmacokinetics of exenatide administered once weekly by SC injection',\n  'pharmacodynamics of exenatide administered once weekly by SC injection in subjects with',\n  'postprandial glucose concentrations',\n  'G1',\n  'pharmacokinetics (PK)',\n  'G1',\n  'Fasting Plasma Glucose',\n  'HbA1c',\n  'patients with',\n  'pharmacodynamics of NOX-E36 in healthy subjects',\n  'patients with',\n  'blood glucose levels',\n  'C-reactive protein)',\n  'regimen of insulin glargine in subjects with',\n  'regimen of insulin glargine in subjects with',\n  'lipids',\n  'patient-reported outcomes.',\n  'vitamin K dietary intakes; TUG (sec); grip',\n  'total body; physical activity',\n  'patients with',\n  'rank test',\n  'self-management behaviors',\n  'blood glucose target goals|Blood glucose level change from',\n  'baseline|Blood pressure change',\n  'profile changes',\n  'Quality of Life',\n  'physical activity level|Initiation of insulin therapy, Proportion of patients using insulin|Switching of anti-diabetic medications',\n  'Diagnosis of abnormal glucose tolerance',\n  'D status on glucose tolerance',\n  'Diurnal Median Curve)|Percent of Time',\n  'CGM Glucose',\n  'After Day',\n  'Inhibition of DPP-4',\n  'After Day 22|WAA',\n  'Concentration|Plasma Glucose',\n  'During Mixed-Meal Tolerance Test (MMTT)',\n  'Documented Symptomatic Hypoglycemia|Change',\n  'Questionnaire (ITSQ) Regimen Inconvenience Domain Score at',\n  'Lifestyle Flexibility Domain Score at',\n  'real-world setting.',\n  'reducing body weight',\n  'blood pressure.|Changes in anti-diabetic treatments|Disease progression (incidence of microvascular',\n  'total remission of type',\n  'blood pressure, cholesterol',\n  'quality of life',\n  'serum vitamin B12 levels between cases',\n  'serum vitamin',\n  'serum vitamin B6 concentrations',\n  'serum vitamin B12 between patients with',\n  'patients with',\n  'vitamin B6 vitamers between',\n  'patients with',\n  'vitamin B6 vitamers between',\n  'patients with',\n  'vascular risk',\n  'postprandial glucose levels in elderly people with',\n  'pharmacokinetic of DM199 after single',\n  'Therapeutic Glycaemic Response of HbA1c',\n  'Fasting Plasma Glucose',\n  'Average of Weeks 20',\n  'Total Daily Dose of Insulin From Baseline',\n  'loss decreases the risk of CVD',\n  'loss reduces over time',\n  'risk of CVD in morbidly obese subjects with T2DM.',\n  'Percentage',\n  'patients reaching HbA1c below 7.0% without confirmed hypoglycemia',\n  'gain|Rate of confirmed hypoglycemic events',\n  'reach their blood glucose target (HbA1c below 7.0%)',\n  'Medication (TSQM-9)',\n  'self-care|Diabetes-related self efficacy|Patient and referring provider satisfaction',\n  \"Alzheimer's disease (AD)\",\n  \"Alzheimer's disease (AD)\",\n  'administration of Acetylsalicylic Acid|Hepatic safety after the',\n  'administration of Acetylsalicylic Acid|Modification in fasting glucose',\n  'administration of Acetylsalicylic acid',\n  'Cognitive Behavioral Therapy Sessions',\n  'Depression Index',\n  'VLDL-TG production',\n  'VLDL-TG oxidation|VLDL-TG subcutaneous adipose',\n  'pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC)',\n  'parameters of exenatide LAR administered weekly',\n  'Mellitus|Change',\n  'fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with',\n  'post-prandial glucose dynamics',\n  'insulin sensitivity (homeostasis model index',\n  'pancreatic beta cell',\n  'retraining (9 months)',\n  'blood glucose',\n  'blood glucose|change',\n  'blood fasting plasma glucose',\n  'blood plasma glucose level|change',\n  'blood insulin',\n  'blood C-peptide level|change in blood active',\n  'blood PYY',\n  'level|change',\n  'blood HbA1c level|change',\n  'blood glycoalbumin',\n  'Insulin',\n  'A1C (Hemoglobin A1c)|7 point profile|CGM Glucose Ranges - Percent of Measurements|Body',\n  '16',\n  'Percentage',\n  'patients having HbA1c under 7%|Percent of time',\n  'Blood glucose (BG)',\n  'blood glucose excursion (AUCBG0-6h)',\n  'blood glucose (BG)',\n  'profiles, fasting',\n  'self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid',\n  'LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with',\n  'postprandial glucose',\n  'HbA1c',\n  'C-peptide, glucagon.',\n  'Insulin',\n  'C peptide',\n  'insulin|Fasting plasma glucose (FPG)|Serum cytokine',\n  'Insulin-sensitivity index derived from',\n  'insulin',\n  'subgroup of patients, insulin-sensitivity assessed by clamp',\n  'profiles derived from muscle',\n  'quality of life',\n  'profile|HS-C Reactive Protein|Aerobic Fitness',\n  'HbA1c',\n  'total mean glucose from continuous glucose monitoring',\n  'variation|Low Blood Glucose',\n  'Blood Glucose',\n  'range below 3.0 mmol/l|Time',\n  'range below 3.9 mmol/l',\n  'Fasting Glucose',\n  'Fasting Glucose',\n  'Reduction in HbA1c of ≥0.5%,',\n  'HbA1c',\n  'C], TC/HDL-C Ratio,',\n  'LDL-C/HDL-C Ratio)|Changes in WBC',\n  'Differential, High-sensitivity C Reactive Protein (hsCRP)',\n  'Rescue Therapy;',\n  'Discontinuation of Study Medication|Response Rates in',\n  'Lifestyle Modification,',\n  'Combination Therapy',\n  'Adverse Events|Number of Participants Discontinuing Study Drug Due to an Adverse Event|Fasting Plasma Glucose (FPG)',\n  'After Single and Multiple Drug Doses',\n  'Weighted Mean Glucose (WMG)|Change From',\n  'HBA1c|Fasting Plasma Glucose|Fasting',\n  'Insulin|Fasting C',\n  'HDL-C',\n  'Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25',\n  'Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement',\n  'total antioxidant activity measurement',\n  'All-causality',\n  'Laboratory Abnormalities Without Regard to Baseline',\n  'Abnormal Vital Signs|Number of Participants With',\n  'Abnormal Electrocardiogram (ECG) Interval',\n  'AUCtau of PF-06882961 on Day 1',\n  'Day 28|Maximum Plasma Concentration (Cmax)',\n  'Day 28|Terminal Half-life (t½)',\n  'Recovered in Urine',\n  'Hours (Ae24)',\n  'Clearance (CLr)',\n  'HbA1c',\n  'Fasting Serum Glucose',\n  'HbA1c',\n  'Fasting Serum Glucose',\n  'protein as pre-meal after a high-fat meal in healthy subjects',\n  'Curve (iAUC -15 - 360 min).|Effect on apolipoprotein B48 of whey',\n  'protein as pre-meal after a high-fat meal in healthy subjects',\n  'Curve (iAUC -15 - 360 min).',\n  'Curve (AUC -15 - 360 min)|Insulin responses measured as incremental Area Under the',\n  'Curve (AUC -15 - 360 min)|Glucagon responses measured as incremental Area Under the',\n  'Curve (AUC -15 - 360 min)|Glucagon-like peptide 1',\n  'Curve (AUC -15 - 360 min)|Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the',\n  'Curve (AUC -15 - 360 min).',\n  'Secretion-Sensitivity Index-2 (ISSI-2).',\n  'HbA1c',\n  'percentage|Fasting Blood Glucose',\n  'Fasting Insulin Level'],\n 'Timepoint': ['12 months',\n  '12 months|Change',\n  '12 months|All',\n  '12 months|Change',\n  '12 months',\n  '14-week',\n  '6 months',\n  '12 months',\n  'Week (',\n  '12 Compared',\n  'Week (',\n  '12 Compared',\n  'Week (',\n  '12 Compared',\n  '2 time',\n  '3-day',\n  '3-day Food Record)',\n  '3 years',\n  'Week 26',\n  '1,5-Anhydroglucitol (1,5-AG)',\n  'Week 26|Change From',\n  '10-Point Self-Monitoring Blood Glucose (SMBG)',\n  'Week 26|Change From',\n  'Week 26|Change From',\n  'Week 26|Change From',\n  'Week 26|Number',\n  '<7%',\n  '2 diabetes',\n  'Week 24',\n  'Week 24',\n  '120-minute',\n  'Week 24',\n  'Week 24',\n  'Week 24',\n  '24 week',\n  '14 and Week 15',\n  '21 months',\n  '3 months',\n  'Week 16|Ratio',\n  'Week 16|Number of daily',\n  'Week 16',\n  '13 weeks',\n  '6-point self-monitored blood glucose (SMBG)',\n  '2 Hours Oral Glucose Tolerance Test',\n  'Week 24',\n  'Week 24|Change from',\n  '14 or 21',\n  '14 or 21',\n  '14 or 21',\n  'Week 24',\n  'Week 24|Percentage',\n  'Week 24|Change From',\n  '2-hour Postprandial',\n  'Week 24|Change From',\n  '2-hour Postprandial',\n  'Week 24',\n  'Week 24',\n  '2-hour Postprandial',\n  'Week 24|Change From',\n  'Week 24|Change From',\n  '2-hour Postprandial',\n  'Week 24',\n  '2 years',\n  '2-years']}"
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictTest"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "results = data_result_df.from_dict(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Unnamed: 0</th>\n      <th>NCTId</th>\n      <th>Condition</th>\n      <th>PrimaryOutcomeMeasure</th>\n      <th>PrimaryTimeFrame</th>\n      <th>SecondaryOutcomeMeasure</th>\n      <th>SecondaryTimeFrame</th>\n      <th>BaselineMeasureTitle</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>1</td>\n      <td>NCT01814787</td>\n      <td>Type 2 Diabetes</td>\n      <td>Number of Children With Documented Risk Factor...</td>\n      <td>12 months</td>\n      <td>nan</td>\n      <td>nan</td>\n      <td>Age, Categorical|Sex: Female, Male|Race/Ethnic...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>2</td>\n      <td>NCT01346033</td>\n      <td>Type 2 Diabetes</td>\n      <td>Validation of SCOUT DS algorithm for detecting...</td>\n      <td>1 day</td>\n      <td>nan</td>\n      <td>nan</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>3</td>\n      <td>NCT04765631</td>\n      <td>Type 2 Diabetes</td>\n      <td>The main outcome is the comparison of total vo...</td>\n      <td>at inclusion for Qualyor patients. (the HRpQCT...</td>\n      <td>nan</td>\n      <td>nan</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>4</td>\n      <td>NCT03979768</td>\n      <td>Type2 Diabetes</td>\n      <td>Number of Participants with undiagnosed type 2...</td>\n      <td>2 months</td>\n      <td>Explore if there was any difference in the num...</td>\n      <td>Baseline</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5</td>\n      <td>NCT02286128</td>\n      <td>Type 2 Diabetes</td>\n      <td>Correlation between NF-кB dependent-proinflamm...</td>\n      <td>2-4 weeks</td>\n      <td>Correlation between NF-кB dependent-proinflamm...</td>\n      <td>2-4 weeks|2-4 weeks</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n</div>",
      "text/plain": "   Unnamed: 0        NCTId        Condition  \\\n0           1  NCT01814787  Type 2 Diabetes   \n1           2  NCT01346033  Type 2 Diabetes   \n2           3  NCT04765631  Type 2 Diabetes   \n3           4  NCT03979768   Type2 Diabetes   \n4           5  NCT02286128  Type 2 Diabetes   \n\n                               PrimaryOutcomeMeasure  \\\n0  Number of Children With Documented Risk Factor...   \n1  Validation of SCOUT DS algorithm for detecting...   \n2  The main outcome is the comparison of total vo...   \n3  Number of Participants with undiagnosed type 2...   \n4  Correlation between NF-кB dependent-proinflamm...   \n\n                                    PrimaryTimeFrame  \\\n0                                          12 months   \n1                                              1 day   \n2  at inclusion for Qualyor patients. (the HRpQCT...   \n3                                           2 months   \n4                                          2-4 weeks   \n\n                             SecondaryOutcomeMeasure   SecondaryTimeFrame  \\\n0                                                nan                  nan   \n1                                                nan                  nan   \n2                                                nan                  nan   \n3  Explore if there was any difference in the num...             Baseline   \n4  Correlation between NF-кB dependent-proinflamm...  2-4 weeks|2-4 weeks   \n\n                                BaselineMeasureTitle  \n0  Age, Categorical|Sex: Female, Male|Race/Ethnic...  \n1                                                NaN  \n2                                                NaN  \n3                                                NaN  \n4                                                NaN  "
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results.head()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3.8.8 64-bit ('base': conda)",
   "name": "python388jvsc74a57bd0aa103bc93a6207848fa67a1515d71b9e40ee492733cad84c02b8df8f3c6dbc5a"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  },
  "orig_nbformat": 2
 },
 "nbformat": 4,
 "nbformat_minor": 2
}